Next-Generation Sequencing for Minimal Residual Disease Surveillance in Acute Lymphoblastic Leukemia: An Update
| Autor: | Cynthia Reyes-Barron, Yi Ding, Paul G. Rothberg, W. Richard Burack |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Neoplasm Residual business.industry Lymphoblastic Leukemia Receptors Antigen T-Cell High-Throughput Nucleotide Sequencing Precursor Cell Lymphoblastic Leukemia-Lymphoma Prognosis Minimal residual disease DNA sequencing Immunophenotyping body regions 03 medical and health sciences 0302 clinical medicine hemic and lymphatic diseases 030220 oncology & carcinogenesis Internal medicine Risk stratification medicine Humans business 030215 immunology |
| Zdroj: | Critical Reviews™ in Oncogenesis. 22:559-567 |
| ISSN: | 0893-9675 |
| Popis: | Monitoring minimal residual disease (MRD) is an important predictor of outcome in acute lymphoblastic leukemia (ALL) and is used in risk stratification, prognosis determination, and therapy guidance. Several laboratory techniques have proven utility for characterizing leukemic cells and following MRD through diagnosis, remission and possible recurrence. Methods for determining MRD are based on the detection of leukemia-specific aberrant immunophenotypes by mulitparameter flow cytometry or the evaluation of leukemia-specific rearranged immunoglobulin or T-cell receptor sequences by quantitative real-time PCR. Next-generation sequencing (NGS) is emerging as a new flexible and sensitive tool to detect MRD, which allows identification of clonal composition and scalable sensitivity depending on sequence coverage. As NGS becomes more accessible and affordable, guidelines should be established for its application to MRD surveillance. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|